Genetic Engineering News publishes an update on the pending IPO at TEMPUS. It's open access here:
It's a little confusing as it intermingles NVIDIA and TEMPUS news. The update includes amendment(s) to the initial TEMPUS IPO documents.
Here's some bullet points, pulled from GEN:
- 11M shares at $35-37, raising ~$400M at a valuation of $6B
- Veracyte market cap, $1.7B
- Guardant market cap, $4B
- Exact Sciences market cap, $8B
- Natera market cap, $14B
- Sales history with 7000 physicians, 200 biotech, 19/20 top pharma
- Data and services 30% of 1Q revenue (so that leaves 70% genomics)
- "Tempus expects AI to grow into a third product line"
- Last year's revenue was $532M (net loss $215M)
